Instil Bio reports Q2 2026 financial results and corporate update
Cash at $69.9M, R&D expenses down to $0.3M, net loss per share $0.63, evaluating acquisitions.
See the latest news and media coverage for Instil Bio. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biotechnology company developing innovative therapies
instilbio.comLast updated
In short: Instil Bio reported its Q2 2026 financial results and continued its strategic shift by evaluating acquisitions after ending key programs.
Cash at $69.9M, R&D expenses down to $0.3M, net loss per share $0.63, evaluating acquisitions.
Cash position of $74.7 million expected to fund operations beyond 2027; actively evaluating acquisitions and in-licensing.
Company evaluating acquisitions and in-licensing; $76.3M cash expected to fund operations beyond 2027.
Under the termination, rights revert to ImmuneOnco, and Axion winds down clinical development of AXN-2510, an investigational therapy.
Instil Bio Inc. research and ratings by Barron's. View TIL revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.
DALLAS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported...
Instil Bio ( (TIL)) has shared an update. On January 5, 2026, Instil Bio’s subsidiary Axion Bio and ImmuneOnco Biopharmaceuticals mutually terminated their August 1...
Instil Bio is calling it quits on its lead tumor-infiltrating lymphocyte therapy and four corresponding programs, a major overhaul of the company's priorities that's resulting...
Track Instil Bio and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Instil Bio and other trending companies.